-
In section: UMass Chan News
In subsection: News Archives
UMass Medical School - Sena-Esteves named outstanding new investigator
Sena-Esteves named outstanding new investigator
Tay-Sachs investigator honored by the American Society of Gene and Cell Therapy
Jim Fessenden
UMass Medical School Communications
Miguel Sena-Esteves, Society of Gene & Cell Therapy (ASGCT), Tay Sachs disease
Miguel Sena-Esteves, PhD Miguel Sena-Esteves, PhD, associate professor of neurology, received the 2011 Outstanding New Investigator Award from the American Society of
Last modified: Dec 26, 2013
-
In section: UMass Chan News
In subsection: News Archives
Miguel Sena-Esteves tells the Washington Post how a rare breed of ancient sheep has played a key role in Tay-Sachs research.
Last modified: May 24, 2016
-
In section: UMass Chan News
In subsection: News Archives
UMass Medical School scientist Miguel Sena-Esteves, PhD, and colleagues are nearing human clinical trials on a gene therapy for Tay-Sachs and Sandhoff diseases.
Last modified: Jul 18, 2017
-
In section: UMass Chan News
In subsection: News Archives
Heather Gray-Edwards, DVM, PhD; Miguel Sena-Esteves, PhD; and Raymond Dunn, MD; are the recipients of the Office of Business Development & Innovation 2021 BRIDGE Fund grants.
Last modified: Jun 18, 2021
-
In section: UMass Chan News
In subsection: News Archives
Learn about the latest advancements in Tay-Sachs research in this Voices of UMassMed podcast with Miguel Sena-Esteves, PhD, and Heather Gray-Edwards, DVM, PhD.
Last modified: Sep 23, 2019
-
In section: UMass Chan News
In subsection: News Archives
Top story: The Translational Institute for Molecular Therapeutics leverages UMass Chan Medical School’s extensive experience in researching and developing gene therapies for early-stage clinical trials. Miguel Sena-Esteves, PhD, is director of the new institute.
Last modified: Dec 26, 2022
-
In section: UMass Chan News
In subsection: News Archives
Jim Fessenden
UMass Medical School Communications
Radio Boston host Jessica Alpert interviewed Miguel Sena-Esteves, PhD, associate professor of neurology, and Carey Goldberg, WBUR Commonhealth reporter, for a segment on a human gene therapy trial for Tay-Sachs disease.
Radio Boston, Tay-Sachs, Miguel Sena-Esteves Miguel Sena-Esteves, PhD Radio Boston host Jessica Alpert interviewed Miguel Sena-Esteves, PhD, associate professor of neurology, and Carey Goldberg, WBUR Commonhealth reporter, for a segment
Last modified: Dec 16, 2013
-
In section: UMass Chan News
In subsection: News Archives
In a piece written for The Conversation, Miguel Sena-Esteves, PhD, talks about research leading to the first ever gene therapy for Tay-Sachs disease and the launch of the Translational Institute for Molecular Therapeutics at UMass Chan.
Last modified: Feb 14, 2022
-
In section: UMass Chan News
In subsection: News Archives
The Translational Institute for Molecular Therapeutics leverages UMass Chan Medical School’s extensive experience in researching and developing gene therapies for early-stage clinical trials. Miguel Sena-Esteves, PhD, is director of the new institute.
Last modified: Feb 10, 2022
-
In section: UMass Chan News
In subsection: News Archives
Tay-Sachs Symposium
Sena-Esteves reports human gene therapy trials may begin next year
Mark Shelton
UMass Medical School Communications
Sena-Esteves, Tay-Sachs
Miguel Sena-Esteves, PhD Breakthroughs in crossing the blood–brain barrier that could lead to new treatments for Tay-Sachs, Canavan and other neurodegenerative diseases were among the research findings presented at the National Tay-Sachs & Allied Diseases (NTSAD) Science Symposium, according to Miguel Sena-Esteves, PhD, associate professor
Last modified: Dec 27, 2013